BEDFORD, Mass., April 23, 2014 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women, will showcase its comprehensive suite of healthcare solutions for women at the 62nd Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG) on April 26th - 30th at the McCormick Place Convention Center in Chicago. ACOG is a professional association of medical doctors specializing in obstetrics and gynecology in the United States. It has a membership of over 55,000 and represents 90 percent of U.S. board-certified obstetrician-gynecologists.

On display from Hologic's Diagnostics division will be the ThinPrep and Aptima HPV cervical cancer screening product lines. The Company will also highlight two minimally invasive surgical products from its GYN Surgical Solutions division that address abnormal uterine bleeding, a condition that affects 1 in 5 women in the United States. The NovaSure endometrial ablation system, which has just reached a milestone 2 million procedures performed worldwide, offers women a clinically proven, safe and effective treatment option for heavy periods. Hologic's MyoSure tissue removal system is a minimally invasive hysteroscopic treatment for the removal of intrauterine pathology including fibroids and polyps. Also featured from the Company's GYN surgical product line will be the Aquilex fluid control system, a high-performance fluid pump and suction system designed to minimize the risk of inaccurate deficit readings while maintaining constant uterine cavity distention throughout the MyoSure procedure; and the Tower-free Hysteroscopy System (THS), a versatile platform designed to meet the diverse diagnostic and treatment needs of the gynecologist's office.

Participants will have the opportunity to use Hologic's GyneSim virtual simulation system, a platform for realistic teaching and training of MyoSure procedures, when they visit the Hologic booth.

The Company will also showcase images from its game-changing Dimensions 3D mammography system on SecurView diagnostic workstations. Both products are part of the Company's Breast Health division. Hologic's 3D mammography technology is clinically proven to increase invasive breast cancer detection rates and reduce anxiety provoking and costly recalls. Hologic is currently the only company to have an FDA approved 3D mammography system and has over 1,500 systems installed worldwide.

Hologic is hosting a special luncheon symposium in the ACOG product theater, "Cutting Edge Breast and Cervical Cancer Screening: Maximizing Benefits, Minimizing Harm," on Tuesday, April 29th from 12 to 1:00 p.m. A panel of experts will address the clinical benefits of Hologic's 3D mammography technology in breast cancer screening and diagnosis and Hologic's Aptima HPV assay, an mRNA-based screening test for cervical cancer screening and how these technologies can lead to more effective screening strategies.

Hologic's game-changing technologies will be on display in booth #601 in the West Building of McCormick Place.

About Hologic, Inc.:

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products. The Company operates four core business units focused on breast health, diagnostics, GYN surgical, and skeletal health. With a comprehensive suite of technologies and a robust research and development program, Hologic is committed to improving lives. The Company is headquartered in Massachusetts. For more information, visit www.Hologic.com.

Hologic, Aptima, Aquilex, Dimensions, MyoSure, NovaSure, SecurView, THS, and ThinPrep are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.

Forward-Looking Statement Disclaimer:

This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the products can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.